Tilray Reports Agreement with Grow Pharma to Import and Distribute Medical Cannabis Products in the UK | Tilray Reports Agreement with Grow Pharma to Import and Distribute Medical Cannabis Products in the UKFinancial Buzz

Tilray Reports Agreement with Grow Pharma to Import and Distribute Medical Cannabis Products in the UK

Tilray Inc. (NASDAQ: TLRY) has reported an agreement with Grow Pharma to import and distribute Tilray’s medical cannabis products with the United Kingdom.  Tilray will provide authorized UK patients with a locally maintained supply of medical cannabis solutions.  The company expects a range of GMP-certified medical cannabis products available for patients within the UK by March 2021.  Patients to use medical cannabis will access Tilray products within the UK by obtaining prescriptions through private practice or the National Health Service.  Brendan Kennedy, Tilray’s Chief Executive Officer, said, “This partnership with Grow Pharma provides patients in need access to a sustained supply of GMP-certified, high-quality medical cannabis and is an important step in improving access in the UK. Tilray will continue to advocate for reasonable patient access to medical cannabis in Europe and countries around the world.”

Sascha Mielcarek, Managing Director of Tilray Europe, said, “As demand continues to ramp up in the UK, Tilray is well-positioned to be a leading supplier of medical cannabis products. Regulations are progressing as more and more countries across Europe are recognizing the benefits of medical cannabis and its potential to improve patients’ quality of life. We’re pleased to reaffirm our commitment to delivering medical cannabis to patients in the UK and look forward to offering a variety of GMP-certified, pharmaceutical-grade products in the coming months.”

Pierre van Weperen, Chief Executive Officer of Grow Pharma, said, “We’re proud to join forces with Tilray and provide patients in need with a secure and sustainable supply of the highest-quality medical cannabis products in the UK.”